Advertisement

Advertisement

ADCT Stock Latest News

ADC Therapeutics Grants One-Time Retention Awards to Executives

Company AnnouncementsADC Therapeutics Grants One-Time Retention Awards to Executives

ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial

PremiumThe Fly

ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial

11d ago

ADC Therapeutics Announces ZYNLONTA-Focused Strategic Reorganization

PremiumCompany Announcements

ADC Therapeutics Announces ZYNLONTA-Focused Strategic Reorganization

17d ago

ADC Therapeutics to reduce workforce by 17% globally

PremiumThe Fly

ADC Therapeutics to reduce workforce by 17% globally

17d ago

ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

PremiumThe Fly

ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

1M ago

ADC Therapeutics price target lowered to $5 from $8 at Stephens

PremiumThe FlyADC Therapeutics price target lowered to $5 from $8 at Stephens

1M ago

ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

The Fly

ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

1M ago

ADC Therapeutics announces positive ZYNLONTA Phase 3 results

Company Announcements

ADC Therapeutics announces positive ZYNLONTA Phase 3 results

1M ago

ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL

PremiumThe Fly

ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL

1M ago

ADC Therapeutics Shareholders Back Governance and Capital Changes

PremiumCompany Announcements

ADC Therapeutics Shareholders Back Governance and Capital Changes

1M ago

Buy Rating Reiterated on Strong Execution and Pipeline Catalysts; 12-Month Price Target Maintained at $8

PremiumRatings

Buy Rating Reiterated on Strong Execution and Pipeline Catalysts; 12-Month Price Target Maintained at $8

2M ago

ADC Therapeutics Balances Solid Quarter With Trial Risk

PremiumCompany Announcements

ADC Therapeutics Balances Solid Quarter With Trial Risk

2M ago

ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year

PremiumThe FlyADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year

2M ago

ADC Therapeutics Ltd (ADCT) Q1 Earnings Cheat Sheet

Pre-Earnings

ADC Therapeutics Ltd (ADCT) Q1 Earnings Cheat Sheet

2M ago

ADC Therapeutics Earnings Call: Trials, Cash And Risks

Company Announcements

ADC Therapeutics Earnings Call: Trials, Cash And Risks

3M ago

ADC Therapeutics: Strengthening Fundamentals, ZYNLONTA Pipeline Momentum, and Increased $8 Target Support Buy Rating

PremiumRatings

ADC Therapeutics: Strengthening Fundamentals, ZYNLONTA Pipeline Momentum, and Increased $8 Target Support Buy Rating

4M ago

ADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright

PremiumThe Fly

ADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright

4M ago

ADC Therapeutics files to sell 9.83M common shares for holders

PremiumThe Fly

ADC Therapeutics files to sell 9.83M common shares for holders

4M ago

ADC Therapeutics reports Q4 adjusted EPS (9c), consensus (27c)

PremiumThe Fly

ADC Therapeutics reports Q4 adjusted EPS (9c), consensus (27c)

4M ago

ADC Therapeutics sees cash runway at least into 2028

PremiumThe FlyADC Therapeutics sees cash runway at least into 2028

4M ago

ADC Therapeutics Ltd (ADCT) Q4 Earnings Cheat Sheet

Pre-Earnings

ADC Therapeutics Ltd (ADCT) Q4 Earnings Cheat Sheet

4M ago

ADC Therapeutics Amends Royalty Deal, Issues New Warrants

Company Announcements

ADC Therapeutics Amends Royalty Deal, Issues New Warrants

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >